Economic Impact of Migraine and Other Episodic Headaches in France
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Migraine is a prevalent and incapacitating condition that affects individuals in the prime of their productive life, thus generating an economic burden for both society and healthcare systems. The direct annual healthcare costs of migraine in France were assessed over 10 years ago, and the current study updates these figures.
Objective: The objective of this study was to determine the economic cost (primarily direct costs) of migraine and other episodic headache in France based on a general population survey of headache, the GRIM2000 (Groupe de Researche Interdisciplinaire sur la Migraine).
Design: From a representative general population sample of 10 585 individuals aged ≥15 years in France in 1999, 1486 individuals experiencing headaches were identified and interviewed regarding healthcare resource consumption in the previous 6 months. By applying unit costs to the resource data, costings (in 1999 values) were determined for physician consultations, hospitalisation, medication use and diagnostic/laboratory tests, and evaluated from a healthcare system perspective. Information on absenteeism and lost productivity was derived from the Migraine Disability Assessment Score (MIDAS) questionnaire.
Results: The prevalence of migraine (including migrainous disorder) was determined to be 17%. Total annual direct healthcare costs were estimated to be €128 per individual with migraine in 1999, corresponding to €1044 million when extrapolated to all individuals experiencing migraine and aged ≥15 years. Around two-thirds of this cost accrued to the social security system (€698 million; €85 per individual). The total annual direct cost of other forms of episodic headache was much lower at €28 per individual (social security cost €18); with a prevalence of 9.2%, the annual national direct cost for other forms of episodic headache totalled €124 million. The principal cost element was physician consultations. However, it was found that many individuals had never consulted a physician for their headaches, and self-medication contributed substantially to the medication costs (the second greatest cost factor for migraine). The cost per individual rose steeply with increasing severity of headache.
Conclusion: The direct healthcare costs of migraine do not seem to have risen significantly over the past decade. A small minority of individuals with more severe headaches consume most of the healthcare resources devoted to migraine, while most individuals generate relatively low direct costs. The total annual direct costs in France for migraine are almost 10-fold higher than those of other episodic headache.
- Ferrari, MD (1998) The economic burden of migraine to society. Pharmacceconomics 13: pp. 667-76 CrossRef
- Clouse, JC, Osterhaus, JT (1994) Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 28: pp. 659-964
- Osterhaus, JT, Gutterman, DL, Plachetka, JR (1992) Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 2: pp. 67-76 CrossRef
- Stang, PE, Osterhaus, JT (1993) Impact of migraine in the United States: data from the National Health Interview Survey. Headache 33: pp. 29-35 CrossRef
- Celentano, DD, Stewart, WF, Lipton, RB (1992) Medication use and disability among migraineurs: a national probability sample survey. Headache 32: pp. 223-8 CrossRef
- Edmeads, J, Findlay, H, Tugwell, P (1993) Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 20: pp. 131-7
- Michel, P, Auray, JP, Chicoye, A (1993) Prise en charge des migraineux en France: coot et recours aux soins: evaluation econorruque de la migraine en France. J Econ Med 11: pp. 71-80
- Kryst, S, Scherl, E (1994) A population-based survey if the social and personal impact of headache. Headache 34: pp. 344-50 CrossRef
- Lipton, RE, Stewart, WF, Celentano, DD (1992) Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med 152: pp. 1273-8 CrossRef
- Stang, PE, Osterhaus, JT, Celentano, DD (1994) Migraine: patterns of healthcare use. Neurology 44: pp. 47-55 CrossRef
- Michel, P, Pariente, P, Duru, G (1996) A population-based, nationwide, comparative survey of access to care in migraine in France. Cephalalgia 16: pp. 50-5 CrossRef
- Michel, P, Dartigues, JF, Lindoulsi, A (1997) Loss of productivity and quality of life in migraine sufferers among French workers: results from the GAZEL cohort. Headache 37: pp. 71-8 CrossRef
- Michel, P, Dartigues, JF, Duru, G (1999) Incremental absenteeism due to headaches in migraine: results from the Mig-Access French national cohort. Cephalalgia 19: pp. 503-10 CrossRef
- Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 8: pp. 1-96
- Bateman, DN (2000) Triptans and migraine. Lancet 335: pp. 860-1 CrossRef
- Leff, RF, Sclar, DA, Nemec, NL (1997) Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care 3: pp. 117-22
- Litaker, DG, Solomon, GD, Genzen, JR (1996) Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 36: pp. 538-41 CrossRef
- Henry, P, Auray, JP, Gaudin, AF (2002) Prevalence and clinical characteristics of migraine in France. Neurology 59: pp. 232-7 CrossRef
- Richard, A, Henry, P, Chazot, G (1993) Qualité de vie et migraine: validation du questionnaire QVM en consultation hospitalière et en médecine générale. Therapie 48: pp. 89-96
- Stewart, WF, Lipton, RE, Whyte, J (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53: pp. 988-94 CrossRef
- El Hasnaoui, A, Vray, M, Richard, A (2003) Assessing the severity of migraine: development of the MIGSEV scale. Headache 43: pp. 628-35 CrossRef
- Vidal, Louis (1999) Dictionnaire Vidal 1999. Paris: Paris Office De Vulgarisation Pharmaceutique.
- UCANSS [online]. Available from URL: http://www.ucanssJr/ucanss.nsn [Accessed 2004 Aug 25]
- Lantéri-Minet, M, Auray, JP, Hasnaoui, A (2003) Prevalence and description of chronic daily headache in the general population in France. Pain 2: pp. 143-9 CrossRef
- Lantéri-Minet, M, Lucas, C, Chaffaut, C (2001) Comportements thérapeutiques des migraineux. Framig 2000 II. Douleur 2: pp. 233-46
- Stewart, WF, Lipton, RB, Celentano, DD (1992) Prevalence of migraine headache in the United States: relation to age, income, race and other sociodemographic factors. JAMA 267: pp. 64-9 CrossRef
- Roijen, L, Essink-Bot, ML, Koopmanschap, MA (1995) Societal perspective on the burden of migraine in the Netherlands. Pharmacoeconomics 7: pp. 170-9 CrossRef
- Hu, XH, Markson, LE, Lipton, RB (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159: pp. 812-8
- Björk, S, Roos, P (1991) Economic aspects of migraine in Sweden. Lund: Institute for Health Economics.
- Blau, JN, Drummond, MF eds. (1991) Migraine. Office of Health Economics, London
- Parry, TG (1992) The prevalence and costs of migraine in Australia. Centre for Applied Economic Research (CAER) working paper n° 1992/1 Kensingyon: University of New South Wales.
- Lipton, RE, Diamond, S, Reed, M (2001) Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 41: pp. 638-45 CrossRef
- Reynaud, M, Gaudin-Colombel, AF, Pen, C (2001) Two methods of estimating health costs linked to alcoholism in France (with a note on social costs). Alcohol Alcohol 36: pp. 89-95 CrossRef
- Boyer, P, Dardennes, R, Even, C (1999) Dépression et santé publique: données et réflexions. Masson, Paris
- Jönsson, B (2002) Revealing the cost of type II diabetes in Europe. Diabetologia 45: pp. 5-12 CrossRef
- Thirouin I. Allergie respiratoire, asthme, environnerrent: un programme pluriannuel de santé publique. Echanges Santé Social 1994: 74
- Lipton, RB, Silberstein, SD (2001) The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 56: pp. 35-42 CrossRef
- Economic Impact of Migraine and Other Episodic Headaches in France
Volume 22, Issue 15 , pp 985-999
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Hôpital Louis Mourier, Colombes, France
- 2. Université Claude Bernard, Lyon, France
- 3. Laboratoire GlaxoSmithKline, Marly-le-Roi, France
- 4. Université de Bordeaux II, Bordeaux, France
- 5. Hôpital Pellegrin, Bordeaux, France
- 6. Hôpital Pasteur, Nice, France
- 7. Hôpital Roger Salengro, Lille, France
- 8. Hôpital Neurologique, Lyon, France